Researchers from The University of Texas MD Anderson Cancer Center presented positive clinical results from two studies today at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
May 31, 2024
0
47
A study by Goethe University Frankfurt points to the possibility that thalidomide derivatives are potentially suitable for treating cancer. Thalidomide was marketed in the 1950s as a sleeping pill. It later gained sad notoriety ...
May 13, 2024
0
70
A novel combination of two cancer drugs has shown great potential as a future treatment for patients with acute myeloid leukemia (AML), one of the most common types of blood cancers. A new study by WEHI researchers has revealed ...
May 1, 2024
0
43
Scientists have found a potential treatment strategy for an aggressive type of leukemia by targeting enzymes used by cells to sense and adapt to oxygen levels.
Apr 18, 2024
0
50
Researchers at Peter Mac have found a new way to treat a form of leukemia that stops the disease in its tracks to prolong remission.
Apr 15, 2024
0
56
Despite having an overall survival rate of 94%, B-cell acute lymphoblastic leukemia (B-ALL), the most common childhood cancer, can prove challenging to treat, with survival among relapsed or resistant cases falling between ...
Apr 8, 2024
0
43
New research from the Royal College of Surgeons in Ireland has found that venetoclax, a medication currently approved for leukemia, provides benefits for patients with multiple myeloma when used in combination with another ...
Mar 25, 2024
0
39
A new research paper titled "ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells" has been published in Oncotarget.
Mar 25, 2024
0
26
Doctors have nearly a dozen new targeted drugs to treat patients with acute myeloid leukemia, or AML, yet three of four patients still die within five years. Some patients succumb within just a month or two, despite the battery ...
Feb 2, 2024
0
57
The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS) and achieved an overall remission rate in 82% of patients with relapsed/refractory mantle cell lymphoma (MCL), ...
Dec 12, 2023
0
60
